Literature DB >> 1976519

Transient electrocardiographic changes suggesting myocardial ischaemia in newborn infants following tocolysis with beta-sympathomimetics.

M Gemelli1, F De Luca, R Manganaro, R Leonardi, F Rando, A Agnetti, C Mami, G Di Pasquale.   

Abstract

Serial electrocardiograms (ECGs) were studied prospectively in 80 apparently healthy newborn infants; 30 infants exposed in utero to prolonged tocolytic therapy (21 to ritodrine and 9 to isoxsuprine) and 50 infants non-exposed in utero to drugs (control group) matched for gestational age, Apgar score, and birth weight. Duration of exposure to tocolysis was at least 30 days (30-180 days) with an oral dosage of 10 mg 3 times daily. ECGs were graded for changes suggestive of ischaemia using the arbitrary grading system described by Jedeikin et al. In all infants with ECG features of myocardial ischaemia, serum creatine-phosphokinase iso-enzyme (CK-MB) activity was measured. Six out of 21 infants to ritodrine and six out of nine infants exposed to isoxsuprine showed a degree of ECG ischaemia which persisted for several weeks. No control infant presented grade 2 or 3 ECG changes after the 5th day of life. The results of this study seem to show that prolonged tocolytic therapy with beta-sympathomimetics has side-effects on the fetal myocardium and suggest that this treatment be reserved only for selective cases and/or for short periods of time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976519     DOI: 10.1007/bf01959533

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  [Transient myocardial ischemia in newborn infants].

Authors:  O Farru; M Rizzardini; N Guzman
Journal:  Arch Mal Coeur Vaiss       Date:  1986-05

2.  Beta-adrenergic effects on rat myometrium: role of cyclic AMP.

Authors:  E A Kroeger; J M Marshall
Journal:  Am J Physiol       Date:  1974-06

3.  Cardiac complications of ritodrine in mother and baby.

Authors:  P Brosset; D Ronayette; M C Pierre; B le Lorier; J J Bouquier
Journal:  Lancet       Date:  1982-06-26       Impact factor: 79.321

4.  Serial electrocardiographic changes in healthy and stressed neonates.

Authors:  R Jedeikin; A Primhak; A T Shennan; P R Swyer; R D Rowe
Journal:  Arch Dis Child       Date:  1983-08       Impact factor: 3.791

5.  Post-partum pulmonary oedema associated with preventive therapy for premature labour.

Authors:  D J Tinga; J G Aarrnoudse
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

6.  [Case report on a myocardial ischemia due to medical tocolysis with ritodrin (pre-par) (author's transl)].

Authors:  G H Ries
Journal:  Geburtshilfe Frauenheilkd       Date:  1979-01       Impact factor: 2.915

7.  Persistent supraventricular tachycardia following infusion with ritodrine hydrochloride.

Authors:  J J Kjer; K H Pedersen
Journal:  Acta Obstet Gynecol Scand       Date:  1982       Impact factor: 3.636

8.  Serum level of ritodrine in man.

Authors:  R Gandar; L W de Zoeten; J B van der Schoot
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

9.  Myocardial ischaemia in asphyxia neonatorum. Electrocardiographic, enzymatic and histological correlations.

Authors:  R A Primhak; R Jedeikin; G Ellis; S K Makela; J E Gillan; P R Swyer; R D Rowe
Journal:  Acta Paediatr Scand       Date:  1985-07

10.  [Cardiotoxic effect of the tocolytic agent fenoterol (partusisten) in the neonate (author's transl)].

Authors:  H Löser; U Steinkamp; K M Müller; J R Pfefferkorn; W R Dame; F Hilgenberg
Journal:  MMW Munch Med Wochenschr       Date:  1981-01-09
View more
  2 in total

1.  Do maternal beta-sympathomimetics influence the development of retinopathy in the premature infant?

Authors:  C A Michie; S Braithwaite; E Schulenberg; D Harvey
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-09       Impact factor: 5.747

Review 2.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.